Altay Therapeutics YCアプリケーション

Winter 2020Active

Altay TherapeuticsはWinter 2020バッチでHealthcare企業としてY Combinatorを卒業しました。以下：会社の事業内容、創業者、そして実際のYCフォームで質問ごとに再構築されたYCへの応募内容。

YCバッチ: Winter 2020
業界: HealthcareTherapeutics
チーム規模: 6
ステータス: Active
ローンチ済み: 2020

創業者

Ali OzesFounder
Osman OzesFounder

Altay Therapeuticsの事業内容

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Altay TherapeuticsのYCアプリケーション、再構築済み

Y Combinator 申請

Altay Therapeutics 様、Winter 2020 バッチ。公開データから回答された、実際のフォームの質問。

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

フルアプリケーションで21件の追加回答

はフルバージョンにあります。無料アカウントを作成して、他のすべてのYCバッチの横にあるYCインサイトで開いてください。

申請内容全体を見る

よくある質問

Altay Therapeuticsの実際のYCアプリケーションですか？

いいえ。Y Combinatorは提出されたアプリケーションを非公開にしています。これは再構築されたものです。実際のYCフォームの質問に、Altay Therapeuticsの公開データ（ローンチノート、創業者経歴、製品説明）から回答しています。Altay Therapeuticsのような会社がYCにどのようにアピールするかを示しており、彼らが提出したテキストではありません。